Welcome to our dedicated page for MacroGenics news (Ticker: MGNX), a resource for investors and traders seeking the latest updates and insights on MacroGenics stock.
MacroGenics, Inc. (NASDAQ: MGNX) is a clinical-stage biopharmaceutical company based in Rockville, Maryland. The company specializes in discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. With a robust pipeline of product candidates, MacroGenics focuses on creating differentiated molecules targeting novel cancer markers, as well as 'bio-betters' designed to improve upon existing therapies.
MacroGenics' flagship product, MARGENZA, is approved for the treatment of adult patients with metastatic HER2-positive breast cancer. The company's pipeline also includes several promising product candidates such as MGC018 (B7-H3), Lorigerlimab (PD-1 × CTLA-4), Tebotelimab (PD-1 × LAG-3), MGD024 (CD123 × CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV × CD3).
The company employs next-generation antibody-based technology platforms, including its proprietary DART® and TRIDENT® platforms, which enable the development of bispecific antibodies. These platforms are instrumental in the creation of MacroGenics' innovative product candidates and have led to several strategic collaborations with global pharmaceutical and biotechnology companies.
MacroGenics' recent achievements include a significant partnership with Gilead Sciences, Inc., focusing on bispecific antibodies. Under this agreement, Gilead has an exclusive option to license worldwide rights to the research program upon achieving pre-defined milestones, potentially earning MacroGenics up to $1.7 billion in target nomination, option fees, and milestone payments, plus tiered double-digit royalties on net sales.
The company is actively engaged in multiple clinical trials and anticipates sharing data from its TAMARACK Phase 2 study of vobramitamab duocarmazine for metastatic castration-resistant prostate cancer by the end of May 2024. Additionally, MacroGenics plans to release its financial results for the fourth quarter of 2023 on March 7, 2024, and for the first quarter of 2024 on May 9, 2024.
For more detailed information, please visit the company's website at www.macrogenics.com.
FAQ
What is the current stock price of MacroGenics (MGNX)?
What is the market cap of MacroGenics (MGNX)?
What does MacroGenics, Inc. do?
What are some key products in MacroGenics' pipeline?
What is MARGENZA?
What technology platforms does MacroGenics use?
What is the significance of MacroGenics' partnership with Gilead Sciences?
When will MacroGenics release its financial results for Q4 2023?
How can I participate in MacroGenics' conference calls?
What is the TAMARACK study?
What are 'bio-betters'?
Where can I find more information about MacroGenics?
